StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.51+0.22 (+1.66%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Trevi Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Trevi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$52.63M. For fiscal 2025 it was -$42.09M. The highest annual figure on record is -$18.29M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.09M–
FY2024Dec 31, 2024-$38.26M–
FY2023Dec 31, 2023-$31.71M–
FY2022Dec 31, 2022-$28.18M–
FY2021Dec 31, 2021-$28.95M–
FY2020Dec 31, 2020-$29.00M–
FY2019Dec 31, 2019-$23.09M–
FY2018Dec 31, 2018-$18.29M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.43M–
Q1 FY2026Mar 31, 2026-$16.69M–
Q4 FY2025Dec 31, 2025-$7.63M–
Q3 FY2025Sep 30, 2025-$10.88M–
Q2 FY2025Jun 30, 2025-$10.10M–
Q1 FY2025Mar 31, 2025-$13.48M–
Q4 FY2024Dec 31, 2024-$9.55M–
Q3 FY2024Sep 30, 2024-$9.56M–
Q2 FY2024Jun 30, 2024-$8.68M–
Q1 FY2024Mar 31, 2024-$10.47M–
Q4 FY2023Dec 31, 2023-$6.36M–
Q3 FY2023Sep 30, 2023-$7.28M–
Q2 FY2023Jun 30, 2023-$9.88M–
Q1 FY2023Mar 31, 2023-$8.20M–
Q4 FY2022Dec 31, 2022-$6.33M–
Q3 FY2022Sep 30, 2022-$8.58M–
Q2 FY2022Jun 30, 2022-$6.18M–
Q1 FY2022Mar 31, 2022-$7.09M–
Q4 FY2021Dec 31, 2021-$6.23M–
Q3 FY2021Sep 30, 2021-$7.24M–
Q2 FY2021Jun 30, 2021-$7.90M–
Q1 FY2021Mar 31, 2021-$7.58M–
Q4 FY2020Dec 31, 2020-$8.92M–
Q3 FY2020Sep 30, 2020-$6.97M–
Q2 FY2020Jun 30, 2020-$8.44M–
Q1 FY2020Mar 31, 2020-$4.67M–
Q4 FY2019Dec 31, 2019-$6.20M–
Q3 FY2019Sep 30, 2019-$7.73M–
Q2 FY2019Jun 30, 2019-$5.06M–
Q1 FY2019Mar 31, 2019-$4.10M–
Q4 FY2018Dec 31, 2018-$4.73M–
Q3 FY2018Sep 30, 2018-$3.99M–
Q2 FY2018Jun 30, 2018-$5.61M–
Q1 FY2018Mar 31, 2018-$3.95M–

More Trevi Therapeutics figures

See a number that looks wrong?